Navigation Links
New and unique treatment for Psoriasis patients

Psoriasis patients who have been long-awaiting new options in treatment, now have fresh hope with the Food and Drug Administration's approval of the new drug, Amevive. This unique drug targets renegade immune cells to control hard-to-treat psoriasis. Psoriasis has been thought to occur when the immune system goes amok and cells called memory effector T cells prompt skin inflammation. The treatments that are currently available for psoriasis range from ointments to ultraviolet therapy to other injected drugs that can broadly suppress// the immune system. The new drug Amevive, however has been designed to target only the harmful T cells, instead of the entire immune system. Physicians have been eagerly awaiting the drug as it works differently from those drugs that are available in the market presently.

The drug, whose effect has not yet been compared with existing treatments, will be marketed in intravenous and intra-muscular injection forms. The treatment, for a 12-week course, will cost between $7000 and $10,000 and the weekly dose will be administered under the supervision of a doctor.

Biogen Inc., the makers of the drug, sponsored a study, which involved patients with chronic psoriasis that covered at least 10 percent of their bodies, and gave them either Amevive or dummy injections. They found that 40 per cent of patients on the Amevive drug saw their psoriasis symptoms cut in half, as compared to about 10 percent of placebo-treated patients. A small number of patients even saw their lesions almost vanish, for at least a while. Though the duration for which the effect lasted was not known, a small subset of patients went seven months or longer before needing additional treatment. The FDA's Dr. Karen Weiss cautioned that though the drug has a much more selective effect, it is still too soon to say it is very selective and very safe. In fact, she added that patients on the drug would require a blood test before each weekly dose to ensure the ir levels of infection-fighting immune cells have not dipped too low, which would require postponing a dose. Another theoretical concern is that by suppressing the immune system, the risk of cancer might increase. The FDA, while not restricting the number of times patients can repeat Amevive therapy when their psoriasis recurs, has warned that the effects of the drug on developing fetus is not yet known.


'"/>




Related medicine news :

1. A unique factor in breathing disorder
2. Pink Shawl Project is a unique initiative
3. Thyroid hormone treatment hastens recovery after cardiac surgery
4. Feeding channel created by malaria parasite - a new target for malaria treatments
5. Now umbilical cord helps in stroke treatment.
6. Now AIDS treatment comes dirt-cheap
7. Breast cancer treatment to be determined by gene test
8. Hemopurifier may revolutionise AIDS treatment
9. New drug helps boost cancer treatment
10. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
11. Experimental treatment for Ebola Virus Shows promising results in mice
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology: